Official Title
Prospective Registry for Multimodal Assessment of Neuromuscular Pathology Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Brief Summary

Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital.

Detailed Description

The prospective registry shall provide new insights into muscular involvement associated with
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. For that reason
consecutive patients with proven corona virus disease 2019 (Covid-19), who are admitted to
the intensive care unit of the department of anesthesiology and intensive care medicine, or
the department of neurology at Tübingen University Hospital, are enrolled. Multimodal
assessment of neuromuscular pathology is based on medical history, laboratory biomarkers
including inflammation parameters and autoimmune antibodies, vital parameters monitoring,
muscle ultrasound, transthoracic echocardiography, electroneurography, as well as
electromyography. Inclusion of follow-up visits permit longitudinal and prognostic evaluation
of diagnostic and therapeutic interventions (e.g. immunomodulation with immunoglobulins,
corticosteroids, or interleukin 6 receptor antagonists).

Unknown status
COVID
SARS-COV2
Corona Virus Infection
Myositis
Myocarditis

Diagnostic Test: laboratory biomarkers

creatine kinase, troponin, urine myoglobin, and autoimmune antibodies

Diagnostic Test: muscle ultrasound

Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)

Eligibility Criteria

Inclusion Criteria:

- Age ≥ 18 years

- Proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

Exclusion Criteria:

- active or known history of myopathy or advanced stage neuropathy

- refusal to participate in clinical research

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Germany
Locations

University Hospital Tuebingen
Tuebingen, Germany

Investigator: Alexander Grimm, MD
Contact: +49 (0) 7071-29
alexander.grimm@med.uni-tuebingen.de

Investigator:

Contacts

Alexander Grimm, MD
+49 (0) 7071-29 - 0
alexander.grimm@med.uni-tuebingen.de

Sven Poli, MD
+49 (0) 7071-29 - 83269
sven.poli@uni-tuebingen.de

University Hospital Tuebingen
NCT Number
MeSH Terms
Infections
Coronavirus Infections
Myositis
Myocarditis